Highlights Amylyx Pharmaceuticals, Inc.

Equities

AMLX

US03237H1014

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-28 EDT			5-day change	1st Jan Change
1.9 ^USD	-1.55%		+6.74%	-87.09%

06-24	Amylyx Pharmaceuticals, Inc.(NasdaqGS:AMLX) dropped from S&P Pharmaceuticals Select Industry Index	CI
06-21	Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar	RE

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Amylyx to buy bankrupt Eiger's experimental drug to treat low blood sugar	06-21	RE
Amylyx Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Amylyx Pharmaceuticals Announces Interim Data from Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram Syndrome	04-10	CI
Sector Update: Health Care Stocks Mixed in Afternoon Trading	04-04	MT
Top Midday Stories: Ford Delays Start of EV Production at Canadian Plant; Alphabet Mulls Acquiring HubSpot; Boeing Paid Alaska Airlines $160 Million in Q1 for Fleet Grounding; Taiwan Semiconductor Expects Full Recovery of Top Plant on Thursday; Coinbase Registered as Restricted Dealer in Canada; CSX Completes First Shipments Using New Rail Post Baltimore Bridge Collapse; Levi Shares Soar on Earnings Beat; Amylyx to Discontinue Marketing Authorizations for Relyvrio	04-04	MT
Amylyx Pharmaceuticals, Inc. Announces Formal Intention to Remove Relyvrio/Albriza from the Market	04-04	CI
North American Morning Briefing : Inflation Data -2-	03-12	DJ
North American Morning Briefing : Stock Futures -2-	03-11	DJ
Health Care Flat After Trial Setbacks -- Health Care Roundup	03-08	DJ
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Friday Ahead of Key Jobs Report	03-08	MT
Amylyx Pharmaceuticals, Inc. Announces Topline Results From Global Phase 3 PHOENIX Trial of AMX0035 in ALS	03-08	CI
Amylyx Pharmaceuticals Swings to Q4 Profit, Net Product Revenue Increases; Shares Rise	02-22	MT
Amylyx Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-22	CI
Amylyx Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-22	CI
Amylyx Pharmaceuticals Announces First Participant Dosed in the Global Phase 3 Orion Study of Amx0035 in Progressive Supranuclear Palsy	12-22	CI
Amylyx Pharmaceuticals, Inc. Announces Publication of Data Showing the Effect of AMX0035 on Plasma Neuroinflammatory Biomarkers in ALS	12-04	CI
Amylyx Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Amylyx Pharmaceuticals, Inc. Announces to Present Clinical Trial Design of ORION, Phase 3 Global Study of AMX0035 in Progressive Supranuclear Palsy, at Neuro2023 PSP and CBD International Research Symposium	23-10-19	CI
Amylyx Pharmaceuticals Says European Medicines Agency Panel Reaffirmed Negative Opinion on Amyotrophic Lateral Sclerosis Drug	23-10-13	MT
Amylyx Pharmaceuticals, Inc. Receives Negative Chmp Opinion on Its Marketing Authorisation Application for Amx0035 for the Treatment of Als in the European Union Following Re-Examination Process	23-10-13	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Amylyx Pharmaceuticals, Inc.

Equities

AMLX

US03237H1014

Highlights

Filters